# Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

> **NCT03507738** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 110 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MT-5625 low dose
- **BIOLOGICAL:** MT-5625 middle dose
- **BIOLOGICAL:** MT-5625 high dose
- **BIOLOGICAL:** Rotarix
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03507738
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-03
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507738, "Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03507738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*